Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta

Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta

Abstract Background Amyloid-β (Aβ) immunotherapy is a promising therapeutic strategy in the fight against Alzheimer’s disease (AD). A number of monoclonal antibodies have entered clinical trials for AD. Some of them have failed due to the lack of efficacy or side-effects, two antibodies are currentl...

Full description

Bibliographic Details
Main Authors: Fadi Rofo, Jos Buijs, Ronny Falk, Ken Honek, Lars Lannfelt, Anna M. Lilja, Nicole G. Metzendorf, Tobias Gustavsson, Dag Sehlin, Linda Söderberg, Greta Hultqvist
Format: Article
Language:English
Published: BMC 2021-09-01
Series:Translational Neurodegeneration
Subjects:
Multivalent antibodies
Alzheimer’s disease
Aβ
Avidity
Oligomers
Protofibrils
Online Access:https://doi.org/10.1186/s40035-021-00258-x

Internet

https://doi.org/10.1186/s40035-021-00258-x

Similar Items